Cytori Therapeutics Inc. (NASDAQ:CYTX) traded down 2.4% during trading on Wednesday . The stock traded as low as $2.03 and last traded at $2.05, with a volume of 61,748 shares. The stock had previously closed at $2.10.

Several equities research analysts recently commented on the stock. Maxim Group reissued a “buy” rating and issued a $75.00 price target on shares of Cytori Therapeutics in a report on Thursday, March 24th. Roth Capital assumed coverage on shares of Cytori Therapeutics in a report on Monday, March 28th. They set a “buy” rating and a $22.50 target price for the company. Finally, Zacks Investment Research lowered shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th.

The stock has a 50 day moving average price of $2.12 and a 200-day moving average price of $2.85. The firm’s market capitalization is $27.33 million.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Tuesday, May 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.38. The firm had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.05 million. During the same quarter in the previous year, the business posted ($0.07) EPS. The company’s revenue was up 26.1% on a year-over-year basis. On average, equities research analysts forecast that Cytori Therapeutics Inc. will post ($1.59) EPS for the current fiscal year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.